Prevalence of Sexual Dysfunction and Hypogonadism in Male Patients with Type 2 Diabetes Mellitus from a Tertiary Care Center in North India

Dr KULDEEP SHARMA; Dr DEEPAK KHANDELWAL; Dr LOVELY GUPTA; Dr SURESH MITTAL; Dr SAMEER AGGARWAL; Dr SACHIN CHITTAWAR

doi:10.59793/yhcnn925

Authors

Dr KULDEEP SHARMA DNB Resident, Dept. of Medicine, Maharaja Agrasen Hospital, Punjabi Bagh, New Delhi, India
Dr DEEPAK KHANDELWAL Senior Consultant Endocrinologist, Dept. of Endocrinology, Khandelwal Diabetes, Thyroid & Endocrinology Clinic, Paschim Vihar, New Delhi, India
Dr LOVELY GUPTA PhD Clinical Researcher, Dept. of Research, Sitaram Bhartia Institute of Science and Research, Qutab Institutional Area, New Delhi, India
Dr SURESH MITTAL Senior Consultant Physician, Dept. of General Medicine, Maharaja Agrasen Hospital, Punjabi Bagh, New Delhi, India
Dr SAMEER AGGARWAL Senior Consultant Endocrinologist, Dept. of Endocrinology, Dr Sameer Aggarwal’s Endocrine Centre, Rohtak, Haryana, India
Dr SACHIN CHITTAWAR Senior Consultant Endocrinologist and Director, Dept. of Endocrinology, Harmony- Dr Sachin’s 360 Degree Diabetes Care, Bhopal, Madhya Pradesh, India

DOI:

https://doi.org/10.59793/yhcnn925

Keywords:

Sexual dysfunction,, hypogonadism,, erectile dysfunction,, testosterone,, type 2 diabetes

Abstract

Diabetes is one of the most common chronic metabolic diseases resulting in sexual dysfunction (SD) in men.
There is limited data regarding SD and testosterone deficiency (hypogonadism) in subjects with type 2 diabetes (T2D) from
India. This study aims to determine the prevalence of SD and hypogonadism, and the correlation of hypogonadism with
complications of diabetes among adult males with T2D from North India. Methods: In this prospective observational study,
people aged 18 to 70 years with T2D (diagnosed for at least 1 year) were evaluated for SD using the International Index of
Erectile Function (IIEF) questionnaire. The demographic, anthropometry, biochemical parameters, and history of microvascular
and macrovascular complications were recorded. In participants with low IIEF score (≤3), serum total testosterone (TT) was
measured twice 4 weeks apart and those with both values <280 ng/dL were defined to have hypogonadism. Results: Among
the 253 patients (55.82 ± 8.42 years) enrolled, the prevalence of SD and hypogonadism was 27.7% and 18.6%, respectively.
Patient on insulin treatment had more odds of hypogonadism likely because of more advanced diseases. Hypogonadism
was significantly associated with the presence of neuropathy and nephropathy (p < 0.0001 and p = 0.0013, respectively).
There was also significant association of hypogonadism with cerebrovascular events and coronary artery disease (p < 0.0001).
Conclusion: There is a high prevalence of SD and hypogonadism in adult males with T2D. Hypogonadism was significantly
correlated with insulin treatment and associated diabetes complications.